Erin Crown, MHS, PA-C, Psych-CAQ

Standardized questionnaires matter, but Erin Crown leans on detailed conversation about a patient's daily routines to catch functional changes that no scale fully captures.

Standardized rating scales define response and remission in clinical trials, but Erin Crown argues real recovery means returning fully to the life a patient had before depression began.

Specialty care approaches shared decision-making differently, and the stakes extend beyond a single symptom. The panel closes this discussion by debating whether treating agitation can shift disease trajectory itself.

With two on-label options now available, the choice between them comes down to comorbidities, psychosis, and risk. The panel also examines how long-term care rating pressures complicate that decision in practice.

A PHQ-9 score can mislead as easily as it clarifies. The panel unpacks the gap between rating-scale remission and how patients actually experience recovery, using real cases where appearances and scores diverged sharply.

Precision medicine looks different in psychiatry than in oncology. The panel discusses why personalizing MDD care starts with a complete patient history, and how clinical experience, evidence, and patient goals combine to guide treatment.

Longer follow-up and real-world claims data add context that pivotal trials alone cannot provide. The panel examines both, alongside how monitoring for response actually happens in daily practice.

A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this antipsychotic therapy was studied and what its data actually show.

Many symptoms that most impair patients with major depressive disorder go unspoken until treatment starts working, making early recognition and patient-defined goals central to effective care.

Depression's cardinal symptoms are often invisible to the patient reporting them. Dr. Harding and Dr. Citrome examine why diagnosis, not treatment, remains psychiatry's hardest task, and how family observation and screening for bipolar depression change the diagnostic path.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

Two on-label options are not enough for every patient. The panel weighs the field's remaining unmet needs against the biological rationale behind a newer, non-antipsychotic approach to treatment.

Decades of off-label prescribing for agitation associated with dementia due to Alzheimer’s are colliding with new evidence and new regulation. The panel examines why practice has lagged behind the data, and what is now changing.

Before any prescription is written, non-pharmacologic strategies and a structured framework guide the panel's approach to agitation, alongside a biological explanation for why redirection so often fails.

Agitation does not stay contained to the patient. The panel examines the data linking agitation to caregiver burden, and the communication gaps that complicate coordinating care across specialties.

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Why behavioral health integration still stalls: workforce shortages, cross-training wins, and collaborative care tips from frontline

Clinicians unpack integrated behavioral health: collaborative care, cross-training, and workforce gaps shaping better outcomes for severe mental illness.

In the first ever episode of "On Your Mind With Erin Crown," explore how tribalism hurts the field of psychiatry and ultimately patient outcomes.

Why psychiatry’s growing “tribalism” harms care—and how clinicians, academia, and pharma can unite to tackle untreated mental illness.

The language clinicians use while talking to postpartum patients is critical. Learn more on best practices in treating this unique patient population.

Long-acting injectables enhance stability and adherence in patients with psychosis, improving long-term outcomes and quality of life, shares Erin Crown, MHS, PA-C, Psych-CAQ.

Explore the complexities of treatment-resistant depression and the vital role of advanced practice providers in enhancing patient care and outcomes.

Panelists discuss how increasing patient comfort with technology and advances in artificial intelligence (AI) and virtual reality (VR) create opportunities for integrating prescription digital therapeutics (PDTs) into schizophrenia care, while emphasizing the need for clinician education and preserving the human connection.

Panelists discuss patient hesitations toward prescription digital therapeutics (PDTs) for schizophrenia. They highlight concerns about repetitive content and technology mistrust due to symptoms such as paranoia, the significant access barriers related to insurance coverage especially for vulnerable populations, and the critical need for improved clinician education to increase awareness and integration of PDTs into treatment plans.

Panelists discuss the flexible use of prescription digital therapeutics (PDTs) in schizophrenia, comparing them with gym workouts that can be used regularly for maintenance or intensified during symptom flare-ups. They highlight PDTs’ role in addressing negative symptoms, supporting sustained improvement, and offering personalized, ongoing care alongside medication.

Panelists discuss the critical role of multimodal care in schizophrenia management, emphasizing that prescription digital therapeutics (PDTs) complement but do not replace medications. They highlight the importance of patient education, shared decision-making, and integrating lifestyle habits to support motivation, symptom control, and long-term well-being.

Panelists discuss ongoing phase 3 studies evaluating prescription digital therapeutics (PDTs) for schizophrenia, focusing on improving negative symptoms such as motivation and pleasure. They highlight how these tools—some incorporating augmented reality—show promise in enhancing self-esteem, reducing defeatist attitudes, and supporting personalized goal setting to boost social functioning and quality of life.